CERE Cerevel Therapeutics Holdings Inc

USD 43.44 0.54 1.258741
Icon

Cerevel Therapeutics Holdings Inc (CERE) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Hold

Average Analyst
Rating
stockTargetAdvisor

Hold

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 43.44

+0.54 (+1.26)%

USD 7.44B

2.18M

USD 45.00(+3.59%)

USD 45.00 (+3.59%)

Icon

CERE

Cerevel Therapeutics Holdings Inc (USD)
COMMON STOCK | NSD
USD 43.44
0.00 0
Take a Tour
stockTargetAdvisor

Hold

Average Analyst
Rating
stockTargetAdvisor

Hold

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 7.44B

USD 45.00 (+3.59%)

USD 43.44

Cerevel Therapeutics Holdings Inc (CERE) Stock Forecast

Show ratings and price targets of :
USD 45.00
(+3.59%)

Based on the Cerevel Therapeutics Holdings Inc stock forecast from 1 analysts, the average analyst target price for Cerevel Therapeutics Holdings Inc is USD 45.00 over the next 12 months. Cerevel Therapeutics Holdings Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Cerevel Therapeutics Holdings Inc is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, Cerevel Therapeutics Holdings Inc’s stock price was USD 43.44. Cerevel Therapeutics Holdings Inc’s stock price has changed by +3.68% over the past week, +4.30% over the past month and +47.30% over the last year.

No recent analyst target price found for Cerevel Therapeutics Holdings Inc
No recent average analyst rating found for Cerevel Therapeutics Holdings Inc

Company Overview Cerevel Therapeutics Holdings Inc

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of...Read More

https://www.cerevel.com

222 Jacobs Street, Cambridge, MA, United States, 02141

355

December

USD

USA

Adjusted Closing Price for Cerevel Therapeutics Holdings Inc (CERE)

Loading...

Unadjusted Closing Price for Cerevel Therapeutics Holdings Inc (CERE)

Loading...

Share Trading Volume for Cerevel Therapeutics Holdings Inc Shares

Loading...

Compare Performance of Cerevel Therapeutics Holdings Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for CERE

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Cerevel Therapeutics Holdings Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc +4.34 (+0.88%) USD126.85B 31.94 20.00

ETFs Containing CERE

Symbol Name CERE's Weight Expense Ratio Price(Change) Market Cap
IBRN
iShares Trust - iShares N.. 3.75 % 0.47 % +0.43 (+1.68%) USD3.84M

Frequently Asked Questions About Cerevel Therapeutics Holdings Inc (CERE) Stock

Based on ratings from 1 analysts Cerevel Therapeutics Holdings Inc's stock is Hold . Stock Target Advisor's fundamental analysis is Bearish. The stock has buy, sell and 1 hold ratings.

Unfortunately we do not have enough data on CERE's stock to indicate if its a good dividend stock.

Based on targets from 1 analysts, the average taret price for CERE is USD 45.00 over the next 12 months. The maximum analyst target price is USD 45 while the minimum anlayst target price is USD 45.

Unfortunately we do not have enough data on CERE's stock to indicate if its overvalued.

The last closing price of CERE's stock was USD 43.44.

The most recent market capitalization for CERE is USD 7.44B.

Based on targets from 1 analysts, the average taret price for CERE is projected at USD 45.00 over the next 12 months. This means that CERE's stock price may go up by +3.59% over the next 12 months.

Following are ETFs with the highest allocation to Cerevel Therapeutics Holdings Inc's stock :

IBRN

As per our most recent records Cerevel Therapeutics Holdings Inc has 355 Employees.

Cerevel Therapeutics Holdings Inc's registered address is 222 Jacobs Street, Cambridge, MA, United States, 02141. You can get more information about it from Cerevel Therapeutics Holdings Inc's website at https://www.cerevel.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...